2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Urinary Bladder Neoplasms
2
Postoperative Complications
2
Neoplasms
2
Malnutrition
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder, Neurogenic
1
Urinary Bladder Diseases
1
Small Cell Lung Carcinoma
1
Frailty
1
Esophagitis
1
Endometriosis
1
Cystitis, Interstitial
1
Cystitis, Hemorrhagic
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
99
Fluorouracil
90
Capecitabine
86
Radiotherapy
81
Dexamethasone
81
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Drug Therapy
65
Leucovorin
64
Cetuximab
60
Erlotinib Hydrochloride
56
atezolizumab
53
Sorafenib
53
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Immunonutrition Diet
×
Clear all
NCT01023412
2025-12-10
IPOD-3
Société des Produits Nestlé (SPN)
Phase NA
Terminated
107 enrolled
NCT02041871
2018-10-11
PROPILS
Assistance Publique - Hôpitaux de Paris
Phase NA
Completed
399 enrolled